Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials

•Elevated vancomycin Etest MICs in MRSA BSI are not associated with adverse outcomes.•The patient's comorbidities rather than vancomycin MIC determine clinical outcome.•Vancomycin MICs vary with the susceptibility testing method used.•Routine Etest MIC testing of MRSA isolates is of limited value for treatment decisions.